Update on treatment of hereditary angioedema

Larisa V. Buyantseva, Niti Sardana, Timothy Craig

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Background: Hereditary Angioedema (HAE) is a rare disease characterized by recurrent, self-limiting episodes of swelling. New therapies have recently emerged and are now available; however, many physicians are not aware of the new medications, and their indications and contraindications. Objective: To update allergists and primary care physicians on new advances in HAE therapies. Data sources: A PubMed literature search was used to develop this manuscript. Study Selections: English language peer-reviewed angioedema articles were selected. High quality Phase II and III placebo-controlled clinical trials were reviewed and summarized. Results: Until 2008, therapy for HAE consisted of symptom relief with narcotics, hydration and fresh frozen plasma (FFP). Androgens and FFP are frequently used despite multiple, significant side effects. Newer therapies include C1-inhibitor - both human plasma derived and recombinant - as well as contact system modulators such as ecallantide and icatibant. All of these products can be used for treatment of acute attacks of HAE, and C1-inhibitors can also be used for prophylaxis. Conclusion: New, disease-specific therapies have recently emerged which are more efficacious, are proven to work by placebo-controlled studies, have minimal adverse effects, and can be utilized for the treatment of HAE.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalAsian Pacific Journal of Allergy and Immunology
Volume30
Issue number2
StatePublished - Jun 1 2012

Fingerprint

Hereditary Angioedemas
Therapeutics
Placebos
Angioedema
Information Storage and Retrieval
Narcotics
Controlled Clinical Trials
Primary Care Physicians
Rare Diseases
PubMed
Androgens
Language
Physicians

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Buyantseva, Larisa V. ; Sardana, Niti ; Craig, Timothy. / Update on treatment of hereditary angioedema. In: Asian Pacific Journal of Allergy and Immunology. 2012 ; Vol. 30, No. 2. pp. 89-98.
@article{6417b37171e74b7eb2325287aefc7e22,
title = "Update on treatment of hereditary angioedema",
abstract = "Background: Hereditary Angioedema (HAE) is a rare disease characterized by recurrent, self-limiting episodes of swelling. New therapies have recently emerged and are now available; however, many physicians are not aware of the new medications, and their indications and contraindications. Objective: To update allergists and primary care physicians on new advances in HAE therapies. Data sources: A PubMed literature search was used to develop this manuscript. Study Selections: English language peer-reviewed angioedema articles were selected. High quality Phase II and III placebo-controlled clinical trials were reviewed and summarized. Results: Until 2008, therapy for HAE consisted of symptom relief with narcotics, hydration and fresh frozen plasma (FFP). Androgens and FFP are frequently used despite multiple, significant side effects. Newer therapies include C1-inhibitor - both human plasma derived and recombinant - as well as contact system modulators such as ecallantide and icatibant. All of these products can be used for treatment of acute attacks of HAE, and C1-inhibitors can also be used for prophylaxis. Conclusion: New, disease-specific therapies have recently emerged which are more efficacious, are proven to work by placebo-controlled studies, have minimal adverse effects, and can be utilized for the treatment of HAE.",
author = "Buyantseva, {Larisa V.} and Niti Sardana and Timothy Craig",
year = "2012",
month = "6",
day = "1",
language = "English (US)",
volume = "30",
pages = "89--98",
journal = "Asian Pacific Journal of Allergy and Immunology",
issn = "0125-877X",
publisher = "The Allergy and Immunology Society of Thailand",
number = "2",

}

Update on treatment of hereditary angioedema. / Buyantseva, Larisa V.; Sardana, Niti; Craig, Timothy.

In: Asian Pacific Journal of Allergy and Immunology, Vol. 30, No. 2, 01.06.2012, p. 89-98.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Update on treatment of hereditary angioedema

AU - Buyantseva, Larisa V.

AU - Sardana, Niti

AU - Craig, Timothy

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background: Hereditary Angioedema (HAE) is a rare disease characterized by recurrent, self-limiting episodes of swelling. New therapies have recently emerged and are now available; however, many physicians are not aware of the new medications, and their indications and contraindications. Objective: To update allergists and primary care physicians on new advances in HAE therapies. Data sources: A PubMed literature search was used to develop this manuscript. Study Selections: English language peer-reviewed angioedema articles were selected. High quality Phase II and III placebo-controlled clinical trials were reviewed and summarized. Results: Until 2008, therapy for HAE consisted of symptom relief with narcotics, hydration and fresh frozen plasma (FFP). Androgens and FFP are frequently used despite multiple, significant side effects. Newer therapies include C1-inhibitor - both human plasma derived and recombinant - as well as contact system modulators such as ecallantide and icatibant. All of these products can be used for treatment of acute attacks of HAE, and C1-inhibitors can also be used for prophylaxis. Conclusion: New, disease-specific therapies have recently emerged which are more efficacious, are proven to work by placebo-controlled studies, have minimal adverse effects, and can be utilized for the treatment of HAE.

AB - Background: Hereditary Angioedema (HAE) is a rare disease characterized by recurrent, self-limiting episodes of swelling. New therapies have recently emerged and are now available; however, many physicians are not aware of the new medications, and their indications and contraindications. Objective: To update allergists and primary care physicians on new advances in HAE therapies. Data sources: A PubMed literature search was used to develop this manuscript. Study Selections: English language peer-reviewed angioedema articles were selected. High quality Phase II and III placebo-controlled clinical trials were reviewed and summarized. Results: Until 2008, therapy for HAE consisted of symptom relief with narcotics, hydration and fresh frozen plasma (FFP). Androgens and FFP are frequently used despite multiple, significant side effects. Newer therapies include C1-inhibitor - both human plasma derived and recombinant - as well as contact system modulators such as ecallantide and icatibant. All of these products can be used for treatment of acute attacks of HAE, and C1-inhibitors can also be used for prophylaxis. Conclusion: New, disease-specific therapies have recently emerged which are more efficacious, are proven to work by placebo-controlled studies, have minimal adverse effects, and can be utilized for the treatment of HAE.

UR - http://www.scopus.com/inward/record.url?scp=84863479695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863479695&partnerID=8YFLogxK

M3 - Review article

VL - 30

SP - 89

EP - 98

JO - Asian Pacific Journal of Allergy and Immunology

JF - Asian Pacific Journal of Allergy and Immunology

SN - 0125-877X

IS - 2

ER -